Repligen shells out $150M for New Hampshire biotech

Waltham drug developer Repligen is paying $150 million in cash and stock to acquire a New Hampshire-based chromatography developer called Avitide Inc. Repligen is spending $75 million cash and another $75 million in stock for the company. Avitide is behind a suite of products for affinity purification, a scientific process used to enhance or separate out biological compounds. The company has created products capable of purifying enzymes, bispeci fic antibodies, hormones, vaccines and gene therapy…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news